Related Experiment Video
Updated: Feb 4, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Editorial commentary: Pulmonary hypertension in left heart disease: Definitions, data sources, and the road ahead
Richa Gupta1, Evan L Brittain1
1Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN and Vanderbilt Translational and Clinical Cardiovascular Research Center, 2525 West End Ave. Suite 300, Nashville, TN 37203, United States.
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Anatomy of the Heart
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Cardiac Catheterization III: Left Heart Catheterization
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

